Sun Pharmaceutical Industries Ltd said its unit has received US Food and Drug Administration's (USFDA) final approval for the generic version of Prevacid.
The approval is for Lansoprazole Delayed-Release Capsules USP, 15 and 30 mg, which are therapeutic equivalents of Takeda Pharmaceutical Co. Ltd's capsules, the company said in a release late on Saturday.
Also read: Indian pharma monthly growth hits record low in Aug
The capsules have annual sales of USD 430 million in the United Sates, it said.
The capsules are used for short-term treatment for healing and symptom relief of active duodenal ulcer, it said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
